Bromotyrosines in sputum proteins and treatment effects of terbutaline and budesonide in asthma

Annals of Allergy, Asthma and Immunology

Volumn 103, Issue 4, 2009, Pages 348-353

  Van Dalen, Christine J ^a,b   Aldridge, Ruth E ^b,c   Chan, Timothy ^b   Senthilmohan, Revathy ^b   Hancox, Robert J ^d   Cowan, Jan O ^d   Taylor, D Robin ^d   Town, G Ian ^b,e   Kettle, Anthony J ^b  

^a MASSEY UNIVERSITY   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c Royal Derby Hospital   (United Kingdom)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e UNIVERSITY OF CANTERBURY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

3 BROMOTYROSINE; 3,5-DIBROMOTYROSINE; 3-BROMOTYROSINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; DIBROMOTYROSINE; DRUG DERIVATIVE; TERBUTALINE; TYROSINE;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOLOGY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EOSINOPHIL; FEMALE; HUMAN; IMMUNOLOGY; LUNG FUNCTION TEST; MALE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SPUTUM;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EOSINOPHILS; FEMALE; HUMANS; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; SPUTUM; TERBUTALINE; TYROSINE; YOUNG ADULT;

EID: 79958127963     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60536-4     Document Type: Article

References (39)

1. Frigas E, Loegering DA, Solley GO, Farrow GM, Gleich GJ. Elevated levels of the eosinophil granule major basic protein in the sputum of patients with bronchial asthma. Mayo Clin Proc. 1981;56:345-353.
2. Venge P, Bystrom J, Carlson M, et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy. 1999;29:1172-1186.
3. Grootendorst DC, van den Bos JW, Romeijn JJ, et al. Induced sputum in adolescents with severe stable asthma. Safety and the relationship of cell counts and eosinophil cationic protein to clinical severity. Eur Respir J. 1999;13:647-653.
4. Koh GCH, Shek LPC, Goh DYT, van Bever H, Koh DSQ. Eosinophil cationic protein: is it useful in asthma? a systemic review. Respir Med. 2007;101:696-705.
5. Lowhagen O, Wever AM, Lusuardi M, et al. The inflammatory marker serum eosinophil cationic protein (ECP) compared with PEF as a tool to decide inhaled corticosteroid dose in asthmatic patients. Respir Med. 2002;96:95-101.
6. Menzies D, Nair A, Lipworth BJ. Non-invasive measurement of airway inflammation in asthma. J Asthma. 2006;43:407-415.
7. Aldridge RE, Hancox RJ, Cowant JO, Frampton CM, Town GI, Taylor DR. Eosinophils and eosinophilic cationic protein in induced sputum and blood: effects of budesonide and terbutaline treatment. Ann Allergy Asthma Immunol. 2002;89:492-497.
8. Mitra SN, Slungaard A, Hazen SL. Role of eosinophil peroxidase in the origins of protein oxidation in asthma. Redox Rep. 2000;5:215-224.
9. van Dalen CJ, Kettle AJ. Substrates and products of eosinophil peroxidase. Biochem J. 2001;358(pt 1):233-239.
10. Wu W, Chen Y, d'Avignon A, Hazen SL. 3-Bromotyrosine and 3,5-dibromotyrosine are major products of protein oxidation by eosinophil peroxidase: potential markers for eosinophil-dependent tissue injury in vivo. Biochemistry. 1999;38:3538-3548.
11. Aldridge RE, Chan T, van Dalen CJ, et al. Eosinophil peroxidase produces hypobromous acid in the airways of stable asthmatics. Free Radic Biol Med. 2002;33:847-856.
12. Wu W, Samoszuk MK, Comhair SA, et al. Eosinophils generate brominating oxidants in allergen-induced asthma. J Clin Invest. 2000;105: 1455-1463.
13. Senthilmohan R, Kettle AJ. Bromination and chlorination reactions of myeloperoxidase at physiological concentrations of bromide and chloride. Arch Biochem Biophys. 2006;445:235-244.
14. van Dalen CJ, Whitehouse MW, Winterbourn CC, Kettle AJ. Thiocyanate and chloride as competing substrates for myeloperoxidase. Biochem J. 1997;327(pt 2):487-492.
15. Kettle AJ. Neutrophils convert tyrosyl residues in albumin to chlorotyrosine. FEBS Lett. 1996;379:103-106.
16. Fu S, Wang H, Davies M, Dean R. Reactions of hypochlorous acid with tyrosine and peptidyl-tyrosyl residues give dichlorinated and aldehydic products in addition to 3-chlorotyrosine. J Biol Chem. 2000;275: 10851-10858.
17. Aldridge RE, Hancox RJ, Robin Taylor D, et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med. 2000;161:1459-1464.
18. Iredale MJ, Wanklyn SA, Phillips IP, Krausz T, Ind PW. Non-invasive assessment of bronchial inflammation in asthma: no correlation between eosinophilia of induced sputum and bronchial responsiveness to inhaled hypertonic saline. Clin Exp Allergy. 1994;24:940-945.
19. Fahy JV, Liu J, Wong H, Boushey HA. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis. 1993;147:1126-1131.
20. Chapman AL, Senthilmohan R, Winterbourn CC, Kettle AJ. Comparison of mono- and dichlorinated tyrosines with carbonyls for detection of hypochlorous acid modified proteins. Arch Biochem Biophys. 2000;377: 95-100.
21. Klebanoff SJ, Locksley RM, Jong EC, Rosen H. Oxidative response of phagocytes to parasite invasion. Ciba Found Symp. 1983;99:92-112.
22. Hadjokas NE, Crowley JJ, Bayer CR, Nielson CP. β-Adrenergic regulation of the eosinophil respiratory burst as detected by lucigenindependent luminescence. J Allergy Clin Immunol. 1995;95:735-741.
23. Tachibana A, Kato M, Kimura H, Fujiu T, Suzuki M, Morikawa A. Inhibition by fenoterol of human eosinophil functions including β2-adrenoceptor- independent actions. Clin Exp Immunol. 2002;130: 415-423.
24. 2-agonists on human granulocyte functions. Int Arch Allergy Immunol. 2006;139:1-8.
25. Nielson CP, Hadjokas NE. β-Adrenoceptor agonists block corticosteroid inhibition in eosinophils. Am J Respir Crit Care Med. 1998;157: 184-191.
26. 2-agonists. Eur Respir J. 1996;9:160-168.
27. Hancox RJ, Stevens DA, Adcock IM, Barnes PJ, Taylor DR. Effects of inhaled β agonist and corticosteroid treatment on nuclear transcription factors in bronchial mucosa in asthma. Thorax. 1999;54:488-492.
28. Winterbourn CC, Kettle AJ. Biomarkers of myeloperoxidase-derived hypochlorous acid. Free Radic Biol Med. 2000;29:403-409.
29. Yoshikawa S, Kayes SG, Parker JC. Eosinophils increase lung microvascular permeability via the peroxidase-hydrogen peroxide-halide system. Bronchoconstriction and vasoconstriction unaffected by eosinophil peroxidase inhibition. Am Rev Respir Dis. 1993;147:914-920.
30. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254-261.
31. Fahy JV. Anti-IgE: lessons learned from effects on airway inflammation and asthma exacerbation. J Allergy Clin Immunol. 2006;117: 1230-1232.
32. Sears MR. Is it safe to use long-acting β-agonists in asthma and chronic obstructive pulmonary disease? implications of recent trials and metaanalyses. Pol Arch Med Wewn. 2008;118:761-766.
33. Walters EH, Bjermer L, Faurschou P, Sandstrom T. The antiinflammatory profile of inhaled corticosteroids combined with salmeterol in asthmatic patients. Respir Med. 2000;94(suppl F):S26 -S31.
34. Profita M, Gagliardo R, Di Giorgi R, et al. Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics. Allergy. 2005;60:323-329.
35. Wallin A, Sue-Chu M, Bjermer L, et al. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J Allergy Clin Immunol. 2003;112:72-78.
36. 2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med. 1999;160(pt 1): 1493-1499.
37. Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med. 2005;172:704-712.
38. Persdotter S, Lindahl M, Malm-Erjefalt M, et al. Cooperative inhibitory effects of budesonide and formoterol on eosinophil superoxide production stimulated by bronchial epithelial cell conditioned medium. Int Arch Allergy Immunol. 2007;143:201-210.
39. Maneechotesuwan K, Essilfie-Quaye S, Meah S, et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest. 2005;128: 1936-1942.